Tristel
Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom, Australia, Germany, Western Europe, and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers device decontamination products, including wipes system, ULT, OPH, Stella system, fuse for … Read more
Tristel (TSTL) - Net Assets
Latest net assets as of December 2025: GBX33.55 Million GBX
Based on the latest financial reports, Tristel (TSTL) has net assets worth GBX33.55 Million GBX as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX45.43 Million) and total liabilities (GBX11.88 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX33.55 Million |
| % of Total Assets | 73.85% |
| Annual Growth Rate | N/A |
| 5-Year Change | 9.67% |
| 10-Year Change | 120.47% |
| Growth Volatility | 21.11 |
Tristel - Net Assets Trend (2003–2025)
This chart illustrates how Tristel's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tristel (2003–2025)
The table below shows the annual net assets of Tristel from 2003 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | GBX32.99 Million | +1.79% |
| 2024-06-30 | GBX32.41 Million | +5.63% |
| 2023-06-30 | GBX30.68 Million | +5.85% |
| 2022-06-30 | GBX28.99 Million | -3.64% |
| 2021-06-30 | GBX30.08 Million | +5.69% |
| 2020-06-30 | GBX28.46 Million | +21.85% |
| 2019-06-30 | GBX23.36 Million | +26.77% |
| 2018-06-30 | GBX18.43 Million | +14.72% |
| 2017-06-30 | GBX16.06 Million | +7.34% |
| 2016-06-30 | GBX14.96 Million | +5.64% |
| 2015-06-30 | GBX14.16 Million | +17.30% |
| 2014-06-30 | GBX12.08 Million | +11.02% |
| 2013-06-30 | GBX10.88 Million | -12.37% |
| 2012-06-30 | GBX12.41 Million | +4.14% |
| 2011-06-30 | GBX11.92 Million | +40.31% |
| 2010-06-30 | GBX8.49 Million | +76.00% |
| 2009-06-30 | GBX4.83 Million | +11.84% |
| 2008-06-30 | GBX4.32 Million | +64.07% |
| 2007-06-30 | GBX2.63 Million | +31.17% |
| 2006-06-30 | GBX2.00 Million | +19.06% |
| 2005-06-30 | GBX1.68 Million | +1193.51% |
| 2004-04-30 | GBX-154.00K | 0.00% |
| 2003-06-30 | GBX-154.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tristel's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1653100000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | GBX15.80 Million | 47.88% |
| Common Stock | GBX478.00K | 1.45% |
| Other Comprehensive Income | GBX1.41 Million | 4.26% |
| Other Components | GBX15.31 Million | 46.41% |
| Total Equity | GBX32.99 Million | 100.00% |
Tristel Competitors by Market Cap
The table below lists competitors of Tristel ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SCAR3F
SA:SCAR3F
|
$22.17K |
|
VUZIX (V7XN.SG)
STU:V7XN
|
$22.17K |
|
NAT ALTERN INTL (NA2.SG)
STU:NA2
|
$22.17K |
|
SPIRENT COMMUNICTS (BW8.SG)
STU:BW8
|
$22.18K |
|
Stelrad Group PLC
LSE:SRAD
|
$22.16K |
|
Biocure Technology Inc
PINK:BICTF
|
$22.14K |
|
IMDEX (IDG.SG)
STU:IDG
|
$22.13K |
|
CHINA RESOURCES GAS (LGX1.SG)
STU:LGX1
|
$22.11K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tristel's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 32,410,000 to 32,991,000, a change of 581,000 (1.8%).
- Net income of 6,640,000 contributed positively to equity growth.
- Dividend payments of 6,658,000 reduced retained earnings.
- New share issuances of 379,000 increased equity.
- Other comprehensive income increased equity by 2,053,999.
- Other factors decreased equity by 1,833,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX6.64 Million | +20.13% |
| Dividends Paid | GBX6.66 Million | -20.18% |
| Share Issuances | GBX379.00K | +1.15% |
| Other Comprehensive Income | GBX2.05 Million | +6.23% |
| Other Changes | GBX-1.83 Million | -5.56% |
| Total Change | GBX- | 1.79% |
Book Value vs Market Value Analysis
This analysis compares Tristel's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 571.28x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-04-30 | GBX-0.01 | GBX392.50 | x |
| 2005-06-30 | GBX0.09 | GBX392.50 | x |
| 2006-06-30 | GBX0.08 | GBX392.50 | x |
| 2007-06-30 | GBX0.11 | GBX392.50 | x |
| 2008-06-30 | GBX0.17 | GBX392.50 | x |
| 2009-06-30 | GBX0.17 | GBX392.50 | x |
| 2010-06-30 | GBX0.26 | GBX392.50 | x |
| 2011-06-30 | GBX0.30 | GBX392.50 | x |
| 2012-06-30 | GBX0.31 | GBX392.50 | x |
| 2013-06-30 | GBX0.28 | GBX392.50 | x |
| 2014-06-30 | GBX0.31 | GBX392.50 | x |
| 2015-06-30 | GBX0.33 | GBX392.50 | x |
| 2016-06-30 | GBX0.34 | GBX392.50 | x |
| 2017-06-30 | GBX0.37 | GBX392.50 | x |
| 2018-06-30 | GBX0.41 | GBX392.50 | x |
| 2019-06-30 | GBX0.51 | GBX392.50 | x |
| 2020-06-30 | GBX0.61 | GBX392.50 | x |
| 2021-06-30 | GBX0.64 | GBX392.50 | x |
| 2022-06-30 | GBX0.61 | GBX392.50 | x |
| 2023-06-30 | GBX0.65 | GBX392.50 | x |
| 2024-06-30 | GBX0.68 | GBX392.50 | x |
| 2025-06-30 | GBX0.69 | GBX392.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tristel utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 20.13%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.29%
- • Asset Turnover: 1.02x
- • Equity Multiplier: 1.37x
- Recent ROE (20.13%) is above the historical average (13.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.00% | 5.22% | 2.50x | 0.00x | GBX129.40K |
| 2005 | 2.32% | 1.30% | 1.04x | 1.72x | GBX-129.40K |
| 2006 | 25.24% | 13.51% | 1.10x | 1.70x | GBX305.50K |
| 2007 | 20.95% | 10.70% | 1.10x | 1.78x | GBX288.00K |
| 2008 | 24.31% | 17.60% | 1.04x | 1.33x | GBX617.50K |
| 2009 | 19.04% | 13.42% | 1.04x | 1.36x | GBX436.40K |
| 2010 | 14.29% | 13.86% | 0.73x | 1.40x | GBX364.80K |
| 2011 | 3.98% | 5.13% | 0.67x | 1.16x | GBX-720.50K |
| 2012 | 5.66% | 6.46% | 0.74x | 1.18x | GBX-543.10K |
| 2013 | -11.46% | -11.97% | 0.83x | 1.16x | GBX-2.37 Million |
| 2014 | 10.61% | 9.64% | 0.89x | 1.23x | GBX74.20K |
| 2015 | 15.64% | 14.45% | 0.90x | 1.20x | GBX799.20K |
| 2016 | 14.05% | 12.29% | 0.91x | 1.26x | GBX606.30K |
| 2017 | 21.28% | 16.85% | 1.01x | 1.25x | GBX1.81 Million |
| 2018 | 17.76% | 14.73% | 0.99x | 1.22x | GBX1.43 Million |
| 2019 | 17.26% | 15.40% | 0.92x | 1.22x | GBX1.70 Million |
| 2020 | 17.92% | 16.10% | 0.77x | 1.44x | GBX2.25 Million |
| 2021 | 12.16% | 11.79% | 0.78x | 1.33x | GBX648.40K |
| 2022 | 3.41% | 3.17% | 0.80x | 1.34x | GBX-1.91 Million |
| 2023 | 14.54% | 12.39% | 0.87x | 1.35x | GBX1.39 Million |
| 2024 | 20.02% | 15.47% | 0.95x | 1.36x | GBX3.25 Million |
| 2025 | 20.13% | 14.29% | 1.02x | 1.37x | GBX3.34 Million |
Industry Comparison
This section compares Tristel's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $69,056,000
- Average return on equity (ROE) among peers: 6.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tristel (TSTL) | GBX33.55 Million | 0.00% | 0.35x | $22.16K |
| Advanced Medical Solutions Group plc (AMS) | $152.44 Million | 13.21% | 0.11x | $57.66K |
| Cambridge Nutritional Sciences plc (CNSL) | $23.38 Million | -9.00% | 0.26x | $579.03 |
| Inspecs Group plc (SPEC) | $31.35 Million | 15.67% | 1.28x | $8.66K |